News and Trends 2 Oct 2020 Huge €62M Series B Boost for Mosa Meat’s Cell-Based Burgers The Netherlands-based food technology company Mosa Meat has raised €62M in a Series B round that will be used to bring its cultured beef products a step closer to the market. The funding round was led by the Luxembourg firm Blue Horizon Ventures in collaboration with the Bell Food Group, M Ventures, and others. Of […] October 2, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
Expert Advice 23 Sep 2020 How to Invest Smart in Biotech Stocks Anyone investing in public biotech companies will find it challenging to answer the key question: does this company have a good chance to create real value? Medical breakthroughs can result in huge revenues, but being the first to develop and commercialize technologies based on cutting-edge research inherently comes with a high risk of failure. In […] September 23, 2020 - 12 minutesmins - By Carlos de Rojas Share WhatsApp Twitter Linkedin Email
Interview 29 Jul 2020 Medical Cannabis: Regulatory Issues, Patient Demand, and Pricing Changes in Germany While the coronavirus pandemic has shaken many industries to their core, the European medical cannabis industry continues to flourish. A number of recent developments in Germany show that the demand for medicinal cannabis is growing. But the German medical cannabis industry is also facing a number of challenges, including an unmet patient demand and a […] July 29, 2020 - 8 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2020 Forbion Raises €185M to Fuel Late-Stage European Biotechs The Dutch life sciences venture capital firm Forbion has bagged €185M in the first closing of a fund aimed at investing in late-stage European biotech companies, which often struggle to raise capital. The main mission of Forbion’s fund — named the Growth Opportunities Fund — is to invest in European life sciences companies raising their […] July 13, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
In Depth 17 Jun 2020 How is European Biotech Rising to the Covid-19 Testing Challenge? Diagnostics have been thrown into the spotlight in the Covid-19 pandemic because of their instrumental role in preventing further infections. However, developing a test for Covid-19 isn’t an easy task. What exactly is needed to make a good Covid-19 test, and how are European biotech companies working to fill this need? While the development of […] June 17, 2020 - 10 minutesmins - By Mark Livingstone Share WhatsApp Twitter Linkedin Email
In Depth 1 Jun 2020 How Personal Genomics Companies Are Changing Drug Development In recent years, companies offering direct-to-consumer genomics tests have started switching the business model and venturing into drug development. Amidst criticism on data protection and lack of transparency, personal genomics companies are leveraging their unique position to generate genomics data to strike lucrative deals with pharma companies. Thanks to cheaper data acquisition and convenient analysis, […] June 1, 2020 - 6 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 28 May 2020 MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience The US-based big pharma MSD has entered the race to be the first to develop an effective vaccine for Covid-19 by acquiring Austrian biotech Themis Bioscience and its vaccine technology for an undisclosed amount. MSD has been a bit slower than some of its contemporaries to announce its plans regarding a potential treatment or vaccine […] May 28, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2020 Update: ADC Therapeutics’ IPO Hits Above Target with €215M Update (15/05/2020): The Swiss biotech ADC Therapeutics has priced its IPO on the New York Stock Exchange far above the initial target of €172M, raising a total of €215.2M ($232.7M). ADC Therapeutics ended up offering more than 12 million shares at a price of €17.57 ($19) per share, which was higher than the €16.65 ($18) […] May 15, 2020 - 4 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 14 May 2020 Oncopeptides’ Share Issue Bags €133M to Take Cancer Drug to Market Swedish biotech Oncopeptides has raised €133M (SEK 1.4B) by issuing new company shares, surpassing expectations and driving the launch of its targeted chemotherapy drug in the US. In what could be one of European biotech’s largest equity boosts this year, the company exceeded initial plans to raise €111M (SEK 1.2M) through Nasdaq Stockholm following a […] May 14, 2020 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2020 Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans Update (29/04/2020): A vaccine developed by the German company BioNTech and its big pharma partner Pfizer has become the first European mRNA vaccine for Covid-19 to enter human testing in a phase I/II trial. Since dosing began last week, twelve volunteers in Germany have been given the vaccine. The first part of the trial — […] April 29, 2020 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2020 Pluristem Scores €50M From EIB to Develop Covid-19 Cell Therapy Israeli cell therapy biotech Pluristem Therapeutics has secured up to €50M in non-dilutive funding from the European Investment Bank to progress its coronavirus-targeting cell therapy to phase III. The partners plan to sign the funding agreement at the end of April and Pluristem will initially receive €20M followed by two further installments totaling up to […] April 29, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2020 UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients The UK company Izana Bioscience is freely providing its phase III-ready anti-inflammatory antibody namilumab in a compassionate use program for the treatment of patients with coronavirus disease in Italy. In severe cases of coronavirus disease, also known as Covid-19, patients experience hyperinflammation. One of the drivers of inflammation is thought to be a protein called […] April 6, 2020 - 2 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email